Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech : Doses First Patient in Phase 2 Trial of Vaccine Candidate in Patients With Advanced Melanoma

06/18/2021 | 05:21am EDT


© MT Newswires 2021
All news about BIONTECH SE
04:59aOmega Diagnostics Group Notes Use of Test in Study Tracking COVID-19 Antibody..
MT
12:20aEMEA MORNING BRIEFING : Stocks to Struggle at -2-
DJ
07/26BIONTECH : provides update on plans to develop sustainable solutions to address ..
PU
07/26BIONTECH : Plans Development of First mRNA-Based Malaria Vaccine
MT
07/26MODERNA : in talks with FDA to expand COVID-19 vaccine pediatric study
RE
07/26PFIZER : Vaccine maker BioNTech to use mRNA tech to target malaria
AQ
07/26MODERNA : FDA asks Pfizer and Moderna to expand COVID-19 vaccine pediatric studi..
RE
07/26MODERNA : At FDA's Urging, Pfizer-BioNTech And Moderna Are Expanding Studies Of ..
RE
07/26BIONTECH : Launches Project to Develop Malaria Vaccine for Africa
MT
07/26GLAXOSMITHKLINE : BioNTech aims to develop mRNA-based malaria vaccine
RE
More news
Financials
Sales 2021 12 451 M 14 671 M 14 671 M
Net income 2021 7 102 M 8 368 M 8 368 M
Net cash 2021 7 718 M 9 094 M 9 094 M
P/E ratio 2021 8,53x
Yield 2021 -
Capitalization 58 566 M 69 138 M 69 004 M
EV / Sales 2021 4,08x
EV / Sales 2022 4,23x
Nbr of Employees 2 200
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 242,49 €
Average target price 155,21 €
Spread / Average Target -36,0%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Sierk Pötting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE251.15%69 138
GILEAD SCIENCES, INC.18.01%86 563
WUXI APPTEC CO., LTD.32.49%67 035
REGENERON PHARMACEUTICALS19.60%59 833
VERTEX PHARMACEUTICALS-15.83%51 496
GENMAB A/S13.72%29 074